Genfit

Yahoo Finance • 3 days ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successful in vivo proof-of-concept results, GENFIT has an exclus... Full story

Yahoo Finance • 3 days ago

GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF

Le candidat-médicament expérimental EViv d'EVerZom, développé pour le traitement de l'ACLF en utilisant sa plateforme propriétaire d'exosomes, représente une approche novatrice en matière de thérapies régénérativesEn cas de résultats posit... Full story

Yahoo Finance • 3 days ago

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025

Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo functional assays expected by... Full story

Yahoo Finance • 3 days ago

GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N dans le traitement de l’ACLF dans le cadre du Liver Meeting® 2025

Des études précliniques ont démontré une efficacité significative sur l'inflammation systémique et le fonctionnement des organes dans des modèles pathologiques d'ACLF.Des données de sécurité issues de l’étude de Phase 1 en cours menée sur... Full story

Yahoo Finance • 14 days ago

GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market

GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiency GENFIT remains listed on the regulated market of Euronext Paris as its primary trading market Lille (Fran... Full story

Yahoo Finance • 16 days ago

GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025

Several posters and presentations featuring new data on three ACLF programs, including G1090N (NTZ reformulation) disease model data, new real-world data and biomarker insights in cirrhosisNew Iqirvo® PBC and PSC data to be presented by pa... Full story

Yahoo Finance • 16 days ago

GENFIT annonce des avancées dans ses programmes ACLF lors du congrès AASLD The Liver Meeting® 2025

Plusieurs posters et présentations avec de nouvelles données relatives à trois de nos programmes dans l’ACLF, dont des données de G1090N dans des modèles précliniques, de nouvelles données en vie réelle, et des données de biomarqueurs dans... Full story

Yahoo Finance • last month

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story

Yahoo Finance • 2 months ago

Genfit S.A. GAAP EPS of -€0.20, revenue of €35.67M

* Genfit S.A. press release [https://seekingalpha.com/pr/20240299-genfit-reports-first-half-2025-financial-results-and-provides-corporate-update] (OTCPK:GNFTF [https://seekingalpha.com/symbol/GNFTF]): 1H GAAP EPS of -€0.20. * Revenue o... Full story

Yahoo Finance • 2 months ago

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major Europe... Full story

Yahoo Finance • 2 months ago

GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société

Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la suite de l'approbation par trois pays eu... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Monday

Major earnings expected after the bell on Monday include: * Genfit S.A. (GNFT [https://seekingalpha.com/symbol/GNFT]) * For Seeking Alpha's full earnings season calendar, click here [https://seekingalpha.com/earnings/earnings-calendar... Full story

Yahoo Finance • 2 months ago

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatenin... Full story

Yahoo Finance • 2 months ago

GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 19 septembre 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du fo... Full story

Yahoo Finance • 2 months ago

3 out of 5 companies miss EPS estimates this week: Earnings Scorecard

[Data analytics dashboard display. Business and financial investment. HUD infographic of financial. Information reports of business strategy for investment. 3d rendering] KanawatTH/iStock via Getty Images Wall Street's major averages cl... Full story

Yahoo Finance • 3 months ago

European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading

European equities traded in the US as American depositary receipts opened the week slightly lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 years ago

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic li... Full story

Yahoo Finance • 3 years ago

The NASH Drug Dream Isn’t Dead Yet. Intercept is Asking FDA for Approval Again.

A newly identified condition thought to affect many adults in Western countries, nonalcoholic Steatohepatitis was once the great hope of the drug development industry.... Full story

Yahoo Finance • 4 years ago

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 20... Full story